Updated April 25 at 4:56pm

MultiCell files second patent application

MultiCell Technologies Inc. has filed a second patent application for a cancer-fighting method and formula to achieve targeted tumor cell death. More

To continue reading this article, please do one of the following.



Sign up to receive Providence Business News' newsletters
and breaking news alerts.  

health care

MultiCell files second patent application

Posted:

WOONSOCKET – MultiCell Technologies Inc. has filed a second patent application for a cancer-fighting method and formula to achieve targeted tumor cell death.

A biopharmaceutical company that develops and tests novel treatments for liver cancer, multiple sclerosis and other diseases, MultiCell Technology has already patented a noncoding double stranded micro RNA (miRNA) called MCT-485, which stimulates immune activity in in vitro models of hepatocellular carcinoma, the most common form of liver cancer. MCT-485 is currently being tested in animal models and is the first in a series of prospective cancer therapeutics being developed by MultiCell Techonology.

The company’s more recent patent application covers a method and formula for directing MCT-485 and other miRNAs towards tumor cells and away from healthy tissue. Only those cells that have the highest capability to grow tumors would a cytotoxic dose of a biologically active agent under this method and formula, leaving tissue not directly involved in the cancer-forming process untouched.

Rhode Island Kids Count, CVS Caremark Corp¸

Comments

No comments on this story | Please log in to comment by clicking here
Please log in or register to add your comment
Latest News